Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 25:7:113.
doi: 10.12688/f1000research.12598.1. eCollection 2018.

Cardio-Oncology: mechanisms of cardiovascular toxicity

Timothy M Markman  1 , Maurie Markman  2
Affiliations
Review

Cardio-Oncology: mechanisms of cardiovascular toxicity

Timothy M Markman et al. F1000Res. .

Abstract

The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and immune checkpoint inhibitors) have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death. In the first of this two-part review series, we focus on what is known and hypothesized about the mechanisms of cardiovascular toxicity from anthracyclines, HER2/ErbB2 inhibitors, immune checkpoint inhibitors, and vascular endothelial growth factor inhibitors.

Keywords: HER2/ErbB2 inhibitors; anthracyclines; cardio-oncology; cardiovascular toxicity; immune checkpoint inhibitors.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Murphy SL, Xu J, Kochanek KD: Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1–117. - PubMed
    1. Oeffinger KC, Mertens AC, Sklar CA, et al. : Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82. 10.1056/NEJMsa060185 - DOI - PubMed
    1. Lipshultz SE, Franco VI, Miller TL, et al. : Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015;66:161–76. 10.1146/annurev-med-070213-054849 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Çetin S, Babaoğlu K, Başar EZ, et al. : Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography. 2017. 10.1111/echo.13743 - DOI - PubMed

    2. F1000 Recommendation

    1. Hequet O, Le QH, Moullet I, et al. : Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–71. 10.1200/JCO.2004.06.033 - DOI - PubMed